China SXT Pharmaceuticals (SXTC) Other Non-Current Liabilities (2019 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Other Non-Current Liabilities of $16563.0 for Q1 2026, down 69.26% year-on-year from $53885.0 in Q1 2025, and up 2.3% on a QoQ basis from $16191.0 in Q3 2025.
China SXT Pharmaceuticals (SXTC) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
China SXT Pharmaceuticals (SXTC) has reported Other Non-Current Liabilities for 8 consecutive years, with $16563.0 the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 69.26% year-over-year to $16563.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16563.0 (down 69.26% YoY) and the FY2026 annual result came in at $16563.0, down 69.26% from the prior year.
- Other Non-Current Liabilities advanced to $16563.0 in Q1 2026 per SXTC's latest filing, from $16191.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for SXTC reached as high as $219740.0 in Q3 2024 and fell as low as $16191.0 in Q3 2025.
- A 5-year average of $112237.1 and a median of $111951.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 90.77% — and 2025, when it plunged 92.63%.
- Year by year, Other Non-Current Liabilities stood at $109411.0 in 2022, then jumped by 33.49% to $146049.0 in 2023, then surged by 50.46% to $219740.0 in 2024, then tumbled by 92.63% to $16191.0 in 2025, then increased by 2.3% to $16563.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $16563.0, $16191.0, and $53885.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | China SXT Pharmaceuticals | 7.11 Mn | -21.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16,563.00 |
| Sep 30, 2025 | 16,191.00 |
| Mar 31, 2025 | 53,885.00 |
| Sep 30, 2024 | 219,740.00 |
| Mar 31, 2024 | 213,571.00 |
| Sep 30, 2023 | 146,049.00 |
| Mar 31, 2023 | 111,951.00 |
| Sep 30, 2022 | 109,411.00 |
| Mar 31, 2022 | 122,773.00 |
| Sep 30, 2021 | 480,227.00 |
| Mar 31, 2021 | 472,282.00 |
| Sep 30, 2020 | 104,814.00 |
| Mar 31, 2020 | 113,611.00 |
| Sep 30, 2019 | 73,533.00 |
| Mar 31, 2019 | 78,317.00 |